Successful early use of anti-SARS-CoV-2 monoclonal neutralizing
antibodies in SARS-CoV-2 infected hematological patients - A
Czech multicenter experience

J 2022

Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience

WEINBERGEROVÁ, Barbora, Ivo DEMEL, Benjamin VISEK, Jan VALKA, Martin CERNAN et. al.

Basic information

Original name

Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience

Authors

WEINBERGEROVÁ, Barbora (203 Czech Republic, guarantor, belonging to the institution), Ivo DEMEL (203 Czech Republic), Benjamin VISEK (203 Czech Republic), Jan VALKA (203 Czech Republic), Martin CERNAN (203 Czech Republic), Pavel JINDRA (203 Czech Republic), Jan NOVAK (203 Czech Republic), Lukas STEJSKAL (203 Czech Republic), Flóra KOVÁCSOVÁ (703 Slovakia, belonging to the institution), Tomáš KABUT (203 Czech Republic, belonging to the institution), Tomas SZOTKOWSKI (203 Czech Republic), Roman HAJEK (203 Czech Republic), Pavel ZAK (203 Czech Republic), Petr CETKOVSKY (203 Czech Republic), Zdeněk KRÁL (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution)

Edition

Hematological Oncology, MALDEN, USA, WILEY-BLACKWELL, 2022, 0278-0232

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.300

RIV identification code

RIV/00216224:14110/22:00125823

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1002/hon.2974

UT WoS

000756686100001

Keywords in English

anti-SARS-CoV-2 monoclonal neutralizing antibodies; bamlanivimab; casirivimab; COVID-19; hematological malignancy; imdevimab; SARS-CoV-2

Abstract

V originále

COVID-19 significantly impairs survival rates among hematological patients when compared to the general population. Our prospective multicentre project analyzed early administration of anti-SARS-CoV-2 spike protein neutralizing monoclonal antibodies (NmAbs) - bamlanivimab (72%) and casirivimab/imdevimab (28%) - efficacy among hematological patients with early-stage COVID-19. Mortality rate was compared to a control cohort of 575 SARS-CoV-2 positive hematological patients untreated with any specific anti-COVID-19 therapy. 88 hematological patients with lymphomas, acute leukemias, and myeloma as their most frequent underlying diagnoses (72%) were evaluated with a 97 days median follow-up after NmAb administration. One third of patients (32%) were treated with an anti-CD20 monoclonal antibody before COVID-19 diagnosis. Median time between first COVID-19 symptom and NmAb administration was 2 days. When administering NmAb, 29%, 57%, 11%, 2%, and 1% of our patients had asymptomatic, mild, moderate, severe, and critical degrees of COVID-19, respectively. 80% of baseline asymptomatic patients remained asymptomatic following NmAb administration. Median duration of COVID-19 symptoms after NmAb administration was 2.5 days. Progression to severe/critical COVID-19 occurred among a total of 17% (15/88) of our cases and numerically higher with bamlanivimab versus casirivimab/imdevimab (21% vs. 8%; p = 0.215), and myelomas (29%), lymphomas (17%) and acute leukemias (18%), respectively. During final follow-up, nine deaths (10%) were recorded - all after bamlanivimab (p = 0.056) with 8% attributed to COVID-19. Regarding "remdesivir/convalescent plasma naive" patients, COVID-19 mortality rates were significantly lower in our NmAbs treated cohort compared to the control cohort of untreated SARS-CoV-2 positive hematological patients (6% vs. 16%, p = 0.020), respectively. Our study validated the safety and efficacy of NmAbs early use among hematological patients with newly diagnosed early-stage COVID-19 in terms of alleviating infection course and decreasing mortality. Results confirmed a more positive effect of a casirivimab/imdevimab combination versus bamlanivimab monotherapy.

Citovat

WEINBERGEROVÁ, Barbora, Ivo DEMEL, Benjamin VISEK, Jan VALKA, Martin CERNAN, Pavel JINDRA, Jan NOVAK, Lukas STEJSKAL, Flóra KOVÁCSOVÁ, Tomáš KABUT, Tomas SZOTKOWSKI, Roman HAJEK, Pavel ZAK, Petr CETKOVSKY, Zdeněk KRÁL and Jiří MAYER. Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience. Hematological Oncology. MALDEN, USA: WILEY-BLACKWELL, 2022, vol. 40, No 2, p. 280-286. ISSN 0278-0232. Available from: https://dx.doi.org/10.1002/hon.2974.

@article{1853633,
   author = {Weinbergerová, Barbora and Demel, Ivo and Visek, Benjamin and Valka, Jan and Cernan, Martin and Jindra, Pavel and Novak, Jan and Stejskal, Lukas and Kovácsová, Flóra and Kabut, Tomáš and Szotkowski, Tomas and Hajek, Roman and Zak, Pavel and Cetkovsky, Petr and Král, Zdeněk and Mayer, Jiří},
   article_location = {MALDEN, USA},
   article_number = {2},
   doi = {http://dx.doi.org/10.1002/hon.2974},
   keywords = {anti-SARS-CoV-2 monoclonal neutralizing antibodies; bamlanivimab; casirivimab; COVID-19; hematological malignancy; imdevimab; SARS-CoV-2},
   language = {eng},
   issn = {0278-0232},
   journal = {Hematological Oncology},
   title = {Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience},
   url = {https://onlinelibrary.wiley.com/doi/10.1002/hon.2974},
   volume = {40},
   year = {2022}
}

TY  - JOUR
ID  - 1853633
AU  - Weinbergerová, Barbora - Demel, Ivo - Visek, Benjamin - Valka, Jan - Cernan, Martin - Jindra, Pavel - Novak, Jan - Stejskal, Lukas - Kovácsová, Flóra - Kabut, Tomáš - Szotkowski, Tomas - Hajek, Roman - Zak, Pavel - Cetkovsky, Petr - Král, Zdeněk - Mayer, Jiří
PY  - 2022
TI  - Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience
JF  - Hematological Oncology
VL  - 40
IS  - 2
SP  - 280-286
EP  - 280-286
PB  - WILEY-BLACKWELL
SN  - 02780232
KW  - anti-SARS-CoV-2 monoclonal neutralizing antibodies
KW  - bamlanivimab
KW  - casirivimab
KW  - COVID-19
KW  - hematological malignancy
KW  - imdevimab
KW  - SARS-CoV-2
UR  - https://onlinelibrary.wiley.com/doi/10.1002/hon.2974
N2  - COVID-19 significantly impairs survival rates among hematological patients when compared to the general population. Our prospective multicentre project analyzed early administration of anti-SARS-CoV-2 spike protein neutralizing monoclonal antibodies (NmAbs) - bamlanivimab (72%) and casirivimab/imdevimab (28%) - efficacy among hematological patients with early-stage COVID-19. Mortality rate was compared to a control cohort of 575 SARS-CoV-2 positive hematological patients untreated with any specific anti-COVID-19 therapy. 88 hematological patients with lymphomas, acute leukemias, and myeloma as their most frequent underlying diagnoses (72%) were evaluated with a 97 days median follow-up after NmAb administration. One third of patients (32%) were treated with an anti-CD20 monoclonal antibody before COVID-19 diagnosis. Median time between first COVID-19 symptom and NmAb administration was 2 days. When administering NmAb, 29%, 57%, 11%, 2%, and 1% of our patients had asymptomatic, mild, moderate, severe, and critical degrees of COVID-19, respectively. 80% of baseline asymptomatic patients remained asymptomatic following NmAb administration. Median duration of COVID-19 symptoms after NmAb administration was 2.5 days. Progression to severe/critical COVID-19 occurred among a total of 17% (15/88) of our cases and numerically higher with bamlanivimab versus casirivimab/imdevimab (21% vs. 8%; p = 0.215), and myelomas (29%), lymphomas (17%) and acute leukemias (18%), respectively. During final follow-up, nine deaths (10%) were recorded - all after bamlanivimab (p = 0.056) with 8% attributed to COVID-19. Regarding "remdesivir/convalescent plasma naive" patients, COVID-19 mortality rates were significantly lower in our NmAbs treated cohort compared to the control cohort of untreated SARS-CoV-2 positive hematological patients (6% vs. 16%, p = 0.020), respectively. Our study validated the safety and efficacy of NmAbs early use among hematological patients with newly diagnosed early-stage COVID-19 in terms of alleviating infection course and decreasing mortality. Results confirmed a more positive effect of a casirivimab/imdevimab combination versus bamlanivimab monotherapy.
ER  -

WEINBERGEROVÁ, Barbora, Ivo DEMEL, Benjamin VISEK, Jan VALKA, Martin CERNAN, Pavel JINDRA, Jan NOVAK, Lukas STEJSKAL, Flóra KOVÁCSOVÁ, Tomáš KABUT, Tomas SZOTKOWSKI, Roman HAJEK, Pavel ZAK, Petr CETKOVSKY, Zdeněk KRÁL and Jiří MAYER. Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience. \textit{Hematological Oncology}. MALDEN, USA: WILEY-BLACKWELL, 2022, vol.~40, No~2, p.~280-286. ISSN~0278-0232. Available from: https://dx.doi.org/10.1002/hon.2974.

Detailed Information on Publication Record